Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

M. Nielsen Hobbs

Executive Editor

Washington DC
M. Nielsen Hobbs has more than 20 years of experience covering the pharmaceutical industry, and writes frequently about the intersection of business, regulation, science and politics. Before joining the “The Pink Sheet” he worked for Congressional Quarterly. Hobbs enjoys discussing BB-8 almost as much as he enjoys talking about 351(k).

Latest From M. Nielsen Hobbs

US FDA Pursuing Two-Track Approach To Regulatory Convergence For Cell and Gene Therapies

Discussions through the WHO are aimed at educating low- and middle-income countries, while efforts with ‘the larger regulators’ aim to reduce the development burden for products targeting ultra-rare diseases, CBER director Peter Marks tell DIA.

Gene Therapy Regenerative Medicine

Peter Marks On How He Wants To Prepare For The Next Pandemic

Acknowledging the toll that vaccine opponents have taken on FDA operations, the CBER director emphasizes the need to create stand-by manufacturing capacity, conduct faster studies in special populations, and better understand the mRNA platform.

Coronavirus COVID-19 Vaccines

User Fee Bill Clears Senate Committee With Importation, Orphan Drug Amendments

Highlighting the much-less-bipartisan atmosphere than the House, ranking member Burr votes against the package; US FDA’s advice to generic applicants could be contentious issue in reconciling the legislation between the two chambers.

User Fees Regulation

The Story of Aduhelm, From Early Studies To Commercial Demise

Our graphical timeline walks you through the most significant events in the history of the Alzheimer’s drug, including the tumultuous last year.

Review Pathway Drug Approval Standards

The Story of Aduhelm, From Early Studies To Commercial Demise

Our graphical timeline walks you through the most significant events in the history of the Alzheimer’s drug, including the tumultuous last year.

Review Pathway Drug Approval Standards

Podcast Special: Assessing US FDA Commissioner Robert Califf’s First 100 Days

Reporters and editors from the Medtech Insight and sister publications covering the pharmaceutical and health, beauty and wellness sectors look at Califf’s goals, accomplishments and trials during the early days of his second term.

FDA Diversity & Inclusion
See All
UsernamePublicRestriction

Register